Literature DB >> 16907697

Uterine artery embolization as a treatment for symptomatic uterine fibroids: a review of literature and case report.

Judy Gainey Seals1, Paul A Jones, Cheryl Wolfe.   

Abstract

PURPOSE: To provide a case presentation and review of the literature on uterine artery embolization (UAE) as a treatment alternative for symptomatic uterine fibroids and to guide the nurse practitioner (NP) in patient selection, education, and periprocedural management of patients undergoing this procedure. DATA SOURCES: Research articles, clinical articles, and case studies pertaining to UAE.
CONCLUSIONS: UAE is a safe, well tolerated, and effective nonsurgical treatment option for symptomatic uterine fibroids. This uterus-sparing procedure has low complication rates with excellent clinical outcomes and high patient satisfaction rates. The majority of women who undergo UAE report marked reduction in the severity of fibroid specific symptoms and significant improvement in their quality of life. Uterine fibroids are common in women and often produce symptoms that have a negative impact on quality of life. IMPLICATIONS FOR PRACTICE: The NP is instrumental in identifying which patients may be appropriate candidates for UAE, educating them about the risks and benefits of the procedure, and managing these patients before and after the procedure.

Entities:  

Mesh:

Year:  2006        PMID: 16907697     DOI: 10.1111/j.1745-7599.2006.00138.x

Source DB:  PubMed          Journal:  J Am Acad Nurse Pract        ISSN: 1041-2972


  2 in total

1.  Successful magnetic resonance imaging-guided focused ultrasound surgery for recurrent uterine fibroid previously treated with uterine artery embolization.

Authors:  Sang-Wook Yoon; Kyoung Ah Kim; Sang Heum Kim; Jong Tae Lee
Journal:  Obstet Gynecol Int       Date:  2010-08-16

2.  Analysis on clinical effects of dilation and curettage guided by ultrasonography versus hysteroscopy after uterine artery embolization in the treatment of cesarean scar pregnancy.

Authors:  Jian Qiu; Yunfeng Fu; Jiewei Xu; Xiaohong Huang; Guorong Yao; Weiguo Lu
Journal:  Ther Clin Risk Manag       Date:  2019-01-07       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.